Bio Pharma R&D Stays Strong Despite Economics
05/04/2010
PhRMA-member companies alone spent an estimated $45.8 billion on pharmaceutical R&D last year, according to the survey. The Burrill & Company analysis shows that non-PhRMA pharmaceutical research companies in the United States spent an estimated $19.5 billion on R&D in 2009.
While companies have been forced to make difficult business decisions, research spending as a percentage of sales remained high in 2009. Over the past nine years, America's pharmaceutical research companies have consistently invested around 18 percent of domestic sales on R&D activities.
"America's biopharmaceutical research sector takes great pride in its global leadership in the development of new life-saving treatments and cures," said PhRMA President and CEO Billy Tauzin.
Project Announcements
Swiss-Based Stadler Expands Salt Lake City, Utah, Operations
09/15/2025
South Korea-Based PPI America Plans Iron County, Utah, Manufacturing Operations
09/15/2025
Apozeal Pharmaceuticals Expands Bucks County, Pennsylvania, Drug Manufacturing Operations
09/14/2025
Georgia-Pacific Expands Monroe County, Alabama, Cellulose Mill Operations
09/14/2025
Noble Plastics Expands St. Landry Parish, Louisiana, Production Operations
09/14/2025
Systems Planning & Analysis Expands Alexandria-Fairfax County, Virginia, Operations
09/13/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025